Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib with Ramucirumab and Paclitaxel in Advanced Esophagogastric Adenocarcinoma
NCT03193918Phase 1Completed
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Apr 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of crenolanib in Esophago-Gastric Adenocarcinoma, sponsored by AROG Pharmaceuticals, Inc. Primary endpoints: Maximum Tolerated Dose at 5 weeks and Response Rate up to 6 months. Started Apr 2017; status: completed.
02
Drugs
crenolanib
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT03193918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193918.